Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis

Next Previous
Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 22 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Efzofitimod (Primary)
  • Indications Pulmonary sarcoidosis
  • Focus Registrational; Therapeutic Use
  • Acronyms EFZO-FIT
  • Sponsors aTyr Pharma

Most Recent Events

  • 19 May 2025 According to an aTyr Pharma media release, the data from this study will be presented at the American Thoracic Society (ATS) 2025 International Conference, which is being held May 16 - 21, 2025, in San Francisco, CA.
  • 13 Mar 2025 According to an aTyr Pharma media release, company held a Type C meeting with the U.S. Food and Drug Administration (FDA) to discuss the statistical analysis plan (SAP) for the Phase 3 EFZO-FIT study.
  • 13 Mar 2025 According to an aTyr Pharma media release, topline data from the study are expected in the third quarter of 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top